Atavistik Bio’s $120 million Series B financing bolsters its push to advance first-in-class, allosteric small-molecule therapies for HHT and MPNs, leveraging its AMPS platform to selectively target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback